APA (7th ed.) Citation

PT, L., W, T., YC, H., TH, W., WT, C., CC, L., . . . CY, L. (2026). Low-Dose Bevacizumab Maintains Efficacy With Reduced Adverse Events in Liver Cancer. Liver international : official journal of the International Association for the Study of the Liver, 46(5), e70617. https://doi.org/10.1111/liv.70617

Chicago Style (17th ed.) Citation

PT, Lin, Teng W, Hsieh YC, Wu TH, Chen WT, Lin CC, Lin SM, and Lin CY. "Low-Dose Bevacizumab Maintains Efficacy With Reduced Adverse Events in Liver Cancer." Liver International : Official Journal of the International Association for the Study of the Liver 46, no. 5 (2026): e70617. https://doi.org/10.1111/liv.70617.

MLA (9th ed.) Citation

PT, Lin, et al. "Low-Dose Bevacizumab Maintains Efficacy With Reduced Adverse Events in Liver Cancer." Liver International : Official Journal of the International Association for the Study of the Liver, vol. 46, no. 5, 2026, p. e70617, https://doi.org/10.1111/liv.70617.